LARS demonstrated incremental value over the presence of LGE (LR χ2 7.82, P = 0.005), atrial fibrillation (LR χ2 9.24, P = 0.002), LV diastolic dysfunction (LR χ2 4.59, P = 0.032), DLCO (LR χ2 9.95, P = 0.002), predicted FVC (LR χ2 8.26, P = 0.004), PASP (LR χ2 5.11, P = 0.024), RV ejection fraction (LR χ2 9.71, P = 0.002), NYHA class II to IV heart failure symptoms (LR χ2 8.49, P = 0.004) and left atrial volume index (LR χ2 7.84, P = 0.005). The gene discussed is CPB1; the disease is heart failure.